Journal of clinical & experimental immunology最新文献

筛选
英文 中文
A Quality Improvement Project to Increase the Rate of HPV Vaccination Initiation in Adolescents 提高青少年HPV疫苗接种率的质量改进项目
Journal of clinical & experimental immunology Pub Date : 2018-11-26 DOI: 10.33140/jcei/03/02/00004
{"title":"A Quality Improvement Project to Increase the Rate of HPV Vaccination Initiation in Adolescents","authors":"","doi":"10.33140/jcei/03/02/00004","DOIUrl":"https://doi.org/10.33140/jcei/03/02/00004","url":null,"abstract":"The vaccination rate of the human papilloma virus vaccine [9vHPV] is low, with only 63% of eligible females and 50% eligible males receiving the vaccine in 2016. The aim of this quality improvement project was to increase the initiation rate of HPV vaccination at Smyrna Pediatrics by 20%, from 3.6% to 4.3% over four weeks. Two physicians, one nurse practitioner, and two medical assistants implemented this quality improvement initiative. There is a lack of education and standardized communication about HPV and 9vHPV to prevent against the virus. A standardized script was created so that all conversations between healthcare professionals and patients and their parents or guardians included the wording of the 9vHPV being recommended rather than optional. Educational material from the CDC was the standard handout given to each adolescent and their parent or guardian. Standardized education and communication was to be provided at each adolescent visit of the 125 eligible adolescents seen during the four-week implementation period, 4% (n = 5) agreed to receive the 9vHPV vaccine. With a baseline of 3.6% (n = 4), there was an 11.1% increase of initiation of 9vHPV. The use of standardized education documents presented to all patients and their parents or guardians established health education as the mainstay of the project and provided information about the importance of prevention and protection from the virus that the vaccine prevents. The implementation of results over a longer period of time may prove to be more effective for the practice’s increase of vaccination rates overall.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77094349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A New Monoclonal Antibody-Based Biosimilar GnRH Antagonist 一种新的基于单克隆抗体的GnRH生物类似药拮抗剂
Journal of clinical & experimental immunology Pub Date : 2018-11-20 DOI: 10.33140/jcei.03.02.07
Gregory M. Lee
{"title":"A New Monoclonal Antibody-Based Biosimilar GnRH Antagonist","authors":"Gregory M. Lee","doi":"10.33140/jcei.03.02.07","DOIUrl":"https://doi.org/10.33140/jcei.03.02.07","url":null,"abstract":"GHR106 is a monoclonal antibody generated against an oligopeptide corresponding to that in the extra cellular domains of human GnRH receptor. The humanized forms of GHR106 exhibit almost identical biological properties to those of decapeptide GnRH antagonists such as Antide and Cetrorelix. The Fc region of humanized GHR106 has been replaced with IgG4 subtype to eliminate activities of effector function. Therefore, the newly humanized GHR106-IgG4Fc can be used clinically as biosimilar GnRH antagonists of higher molecular size, and longer half-life (hrs. vs. days) for therapeutic treatments of fertility-related health conditions without complications arising from the effector functions of immunoglobulins.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"88 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79733852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Still Rare Case of Congenital Afibrinogenemia 一例罕见的先天性纤维蛋白原血症
Journal of clinical & experimental immunology Pub Date : 2018-11-06 DOI: 10.33140/jcei/03/02/00002
I. Tlamçani, A. Krich, Fatima Zahrae El Hamdi, M. A. Hassani
{"title":"A Still Rare Case of Congenital Afibrinogenemia","authors":"I. Tlamçani, A. Krich, Fatima Zahrae El Hamdi, M. A. Hassani","doi":"10.33140/jcei/03/02/00002","DOIUrl":"https://doi.org/10.33140/jcei/03/02/00002","url":null,"abstract":"Congenital afibrinogenemia is characterized by the decrease or the absence of fibrinogen synthesis. It is a rare pathology that is transmitted autosomal recessive mode, with variable clinical demonstrations. The biological diagnosis consists in the presence of traces or absence of fibrogen with blood incoagulability. The coverage of this disease bases itself on the preventive treatment and replacement therapy based on fresh frozen plasma or fibrinogen concentrate. Through this case, we recall the various aspects of these rare condition clinical, biological, genetical as well as therapeutic plans.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80177110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protective Effect of Myrianthus Arboreus Leaves Aqueous Extract in AcetaminophenInduced Liver Toxicity in Rats 豆蔻叶水提物对对乙酰氨基酚所致大鼠肝毒性的保护作用
Journal of clinical & experimental immunology Pub Date : 2018-11-01 DOI: 10.33140/jcei/03/02/00001
{"title":"Protective Effect of Myrianthus Arboreus Leaves Aqueous Extract in AcetaminophenInduced Liver Toxicity in Rats","authors":"","doi":"10.33140/jcei/03/02/00001","DOIUrl":"https://doi.org/10.33140/jcei/03/02/00001","url":null,"abstract":"Owning to changes in living pattern of humans and constant environmental changes, different life challenging diseases now exist. Traditional system has clam that some of these diseases could be cured with plant. Plants and their components are source of large amount of drugs. This study was design to examine the protective effect of Myrianthus arboreus leaves extract against acetaminophen induced liver toxicity in rats. A suspension of 750 mg/kg acetaminophen was administered once every 72 hours to induce toxicity in the rats. Oral administration of 500, 1000 and 2000 mg/kg body weight of the extract and 100 mg/kg of silymarine (reference drug) were administered for 10 days. The result of effect of pretreatment with Myrianthus aboreus leaves on the enzyme makers of tissue damage in acetaminophen induced toxicity showed significant different when compared with the result of group induced without pretreatment. The values of AST, ALT and ALP in the untreated group significantly (p<0.05) increased. Elevated serum level in these enzymes revealed the integrity and functionality of the liver. Thus the increased value of these enzymes indicates damage to the liver by the induced acetaminophen. Also the values of non-enzyme markers (T.B., ALB and TG) for the treated groups decreased when compared with the untreated group. The significant different in the values between the groups pretreated with Myrianthus aboreus leaves and the untreated group showed that MA extract could protect the liver.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89580653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epstein - Barr virus Reactivation Associated with an Increased Thymidine Kinase and Normalized by an Immuno Modulatory Nano-Therapy: Three Case Reports Epstein - Barr病毒再激活与胸苷激酶增加相关,并通过免疫调节纳米疗法正常化:三例报告
Journal of clinical & experimental immunology Pub Date : 2018-07-07 DOI: 10.33140/jcei/03/01/00001
{"title":"Epstein - Barr virus Reactivation Associated with an Increased Thymidine Kinase and Normalized by an Immuno Modulatory Nano-Therapy: Three Case Reports","authors":"","doi":"10.33140/jcei/03/01/00001","DOIUrl":"https://doi.org/10.33140/jcei/03/01/00001","url":null,"abstract":"Epstein-Barr Virus (EBV), a common human herpes virus known to infect most of the world population, has been mentioned in the context of many diverse human pathologies while its participation during its latency phase is more and more often demonstrated in a growing number of chronic malignancies.The biological diagnosis of the virus activity is carried out using serological parameters on the one hand, and the measurement of the viral load on the other hand. Thymidine kinase (TK) is a key enzyme in the regulation of the intranuclear thymidine pool during cell cycle progression. The rise in its plasma level therefore systematically reveals an uncontrolled cellular proliferation evoking, of course, at first a neoplastic process. Nevertheless, EBV being a DNA virus, its reactivation or even a persistent primary infection are also likely to cause an increase in the blood level of TK.Using three examples, we will show that the neutralization of EBV by an immunomodulatory nano-therapy called Bio Immune (G)ene Medicine (BI(G)MED), is accompanied by a normalization of plasma levels of TK, thus underlining the close link between the virus and this marker of cell proliferation.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91083766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Q&A on the Paper of Kurukulasuriya et al. (2017) on IBD Vaccine Efficacy Againsta Canadian Variant IBDV Strain in Broiler Chickens Kurukulasuriya等人(2017)关于IBD疫苗对肉鸡加拿大变异IBDV株有效性的论文答疑
Journal of clinical & experimental immunology Pub Date : 2018-06-13 DOI: 10.33140/jcei/03/01/00003
{"title":"Q&A on the Paper of Kurukulasuriya et al. (2017) on IBD Vaccine Efficacy Against\u0000a Canadian Variant IBDV Strain in Broiler Chickens","authors":"","doi":"10.33140/jcei/03/01/00003","DOIUrl":"https://doi.org/10.33140/jcei/03/01/00003","url":null,"abstract":"Kurukulasuriya, et al. (2017) are reporting the efficacy of two IBD vaccines against an early (6 days post-hatch) challenge\u0000with a variant Canadian IBDV strain in broilers. A modified live vaccine(UNIVAX BD) administered by SQ route at 1 dayof-age delayed infection whereas an HVT-IBD vector vaccine (VAXXITEK HVT+IBD) administered in ovodid not protect.\u0000Furthermore, the authors suggested that the HVT-IBD vector induced immunosuppression responsible for an earlier IBDV\u0000challenge strain replication in the bursa.\u0000The data presented in the paper showed no evidence of VAXXITEK HVT+IBD vaccine take since the mean IBD ELISA\u0000antibody titer at D35 in the vaccinated/non-challenged group was not significantly different from that of the non-vaccinated\u0000group. It wasmuch lower than the expected one based on previous studies performed in the same conditions : in ovo\u0000vaccination of broilers [1,2]. Since there is no evidence of vaccine take, the other potential effects (immunosuppression and\u0000earlier IBDV replication in the bursa) observed in that group cannot be attributed to the vaccine.\u0000Since its launch in 2006 in Brazil, VAXXITEK HVT+IBD has been licensed in more than 75 countries and more than 80\u0000billion birds have been vaccinated. VAXXITEK HVT+IBD is protecting against a wide variety of IBDV strains including\u0000the classical, the very virulent and different variant strains. To our knowledge, noabsence of efficacy nor bursa depletions\u0000have been so far officially reported as long as the vaccine has been administered properlyto healthy embryonated eggs or\u0000to healthy one-day-old chicks.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"40 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76634613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is COVID-19 an Immune Complex Disease and are Billions Vaccinated Concomitantly Dosed with an Immunomodulatory Effector-Checkpoint Viral Mimetic Fc Receptor ? COVID-19是一种免疫复合物疾病吗?数十亿接种疫苗的人是否同时服用免疫调节效应-检查点病毒模拟Fc受体?
Journal of clinical & experimental immunology Pub Date : 1900-01-01 DOI: 10.33140/jcei.06.02.04
{"title":"Is COVID-19 an Immune Complex Disease and are Billions Vaccinated Concomitantly Dosed with an Immunomodulatory Effector-Checkpoint Viral Mimetic Fc Receptor ?","authors":"","doi":"10.33140/jcei.06.02.04","DOIUrl":"https://doi.org/10.33140/jcei.06.02.04","url":null,"abstract":"COVID-19 has often been presented as a hundred diseases of diverse systems and organs needing many specialist experts to study and treat each aspect of this vast scope of pathological complexity in isolation. Alternatively, over the preceding decades, the Merck Manual, numerous publications, and certain patents have described systemic antigen-antibody immune complex diseases caused by viral and other infections with diverse symptoms similar to those of COVID-19. COVID-19 and systemic immune complex disease also selectively impact the same risk groups. Although, immune complex has been identified at sites of COVID-19 pathology in several publications, a recent study reported the unexpected finding that circulating immune complex (CIC) is not elevated in sera or a good biomarker for COVID-19 pathology.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82516765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Study of Clinical-Pathological Discrepancies in Autopsies 尸检临床病理差异的研究
Journal of clinical & experimental immunology Pub Date : 1900-01-01 DOI: 10.33140/jcei.06.02.03
{"title":"Study of Clinical-Pathological Discrepancies in Autopsies","authors":"","doi":"10.33140/jcei.06.02.03","DOIUrl":"https://doi.org/10.33140/jcei.06.02.03","url":null,"abstract":"Background: Autopsy is a traditional method in pathology for the study of diseases or injuries, being key to elucidate the cause of death. However, the number of autopsies has been decreasing progressively. Design and Context: Retrospective cross-sectional study to analyze the presence of discrepancy between clinical and pathological diagnoses as to the cause of death according to the Goldman criteria, verify the epidemiological profile of the main causes of death, and tabulate the number of procedures conducted annually. Method: Analyzing clinical records and autopsy reports from the Department of Pathology and Legal Medicine of the Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA) from 1963 to 2012 and performing statistical analysis on the data collected. Results: The predominant age group was of dead fetuses (30.6% of all cases). The main cause of death was infection (68.4% of diagnoses). After a peak in the early 1980s, there was a progressive drop in the rates of postmortem examination. In the 1990s, the average number of autopsies fell by 58% in relation to the previous decade, and the last decade of the Century registered a decrease of 80% as compared to the average of the 1980s. According to the Goldman criteria, there was discrepancy between ante- and postmortem diagnoses as to the cause of death in 26.2% of the cases. Conclusion: The rates of discrepancy between clinical diagnoses and autopsy findings regarding the cause of death remain high, even though medicine has become more and more advanced in technology.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"72 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74139460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low ASH1L Expression as Potential Diagnostic and Prognostic Biomarker for Renal Cell Carcinoma 低ASH1L表达作为肾细胞癌的潜在诊断和预后生物标志物
Journal of clinical & experimental immunology Pub Date : 1900-01-01 DOI: 10.33140/jcei.06.02.05
{"title":"Low ASH1L Expression as Potential Diagnostic and Prognostic Biomarker for Renal Cell Carcinoma","authors":"","doi":"10.33140/jcei.06.02.05","DOIUrl":"https://doi.org/10.33140/jcei.06.02.05","url":null,"abstract":"As an important methyltransferase, ASH1L played main roles in cell differentiation, embryonic development and autoimmune response. It had been reported that its abnormal expression was closely related to the progression of some diseases. In the current study, we found that ASH1L was low expressed in renal cell carcinoma, and its low expression was positively correlated with tumor progression. Patients with low ASH1L expression had poor OS and RFS, and it had excellent clinical diagnostic value. Furthermore, lower ASH1L expression in dead than survival patients, and multivariate regression Cox analysis confirmed that low ASH1L expression was a predictor for poor prognosis of patients with renal cell carcinoma. Gene-set-enrichment-analysis showed that the DNA-repair, reactive-oxygen-species pathway and Myc-target V2 signaling were significantly enriched to the low ASH1L expression phenotype. Taking together, our findings demonstrated that the low ASH1L expression was likely to be useful as a promising prognostic indicator for renal cell carcinoma.","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81931745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stroke and Adverse Effects on The Immune and Cardiovascular Systems: The Danger of the Rise and Use of Psychedelic Drugs for Depression and PTSD 中风和对免疫和心血管系统的不良影响:抑郁症和创伤后应激障碍致幻剂的增加和使用的危险
Journal of clinical & experimental immunology Pub Date : 1900-01-01 DOI: 10.33140/jcei.06.02.01
{"title":"Stroke and Adverse Effects on The Immune and Cardiovascular Systems: The Danger of the Rise and Use of Psychedelic Drugs for Depression and PTSD","authors":"","doi":"10.33140/jcei.06.02.01","DOIUrl":"https://doi.org/10.33140/jcei.06.02.01","url":null,"abstract":"Depression and post-traumatic stress disorder (PTSD), in the past two decades, has been a growing problem among adults and our youth. For hundreds, if not thousands of years, plant-based psychedelic drugs, such as psilocybin and peyote, have been utilized for medical purposes by numerous native tribal people As early as 1950, lysergic acid diethylamide (LSD), a synthetic mood-altering drug, a report was published that this drug and other psychedelics could be useful in the treatment of psychological and psychiatric problems [1].","PeriodicalId":73657,"journal":{"name":"Journal of clinical & experimental immunology","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81181831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信